European Commission clears Baxter acquisition of Gambro at Phase I subject to conditions

European Commission clears Baxter acquisition of Gambro at Phase I subject to conditions

The European Commission has approved Baxter's acquisition of Swedish medical technology rival Gambro, subject to the divestment of Baxter's Continuous Renal Replacement Therapy business (CRRT). However, the Commission did not find competition concerns arising from the parties' activities in relation to the market for haemodialysis (HD), despite significant overlaps in a number of European countries. After reviewing a range of evidence, including CRA analysis of a large scale bidding dataset constructed by the parties and their advisors on the basis of tender documents, the Commission concluded that Baxter and Gambro were not particularly close competitors in HD, and would continue to face "significant competition from a range of dynamic market participants".

CRA advised Baxter on the antitrust analysis of the deal in a number of jurisdictions, including Europe. In Europe the CRA team including Cristina Caffarra, Bob Stillman, Raphaël de Coninck, Diana Jackson, Rebecca Fordham, Dennis Beling and Tom Traill provided advice, analysis, and assistance with the very large tender data collection exercise required by the Commission.